BioNTech SE (BNTX)

109.03 -3.30 (-2.94%) At close: 4:00PM EST

BioNTech SE

An der Goldgrube 12
Mainz 55131
Germany
49 6131 9084 0
http://www.biontech.de

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 1,800

Key executives

Name	Title	Pay	Exercised	Year born
Prof. Ugur Sahin M.D.	Co-Founder, CEO & Member of Management Board	N/A	N/A	1966
Dr. Sierk Poetting Ph.D.	CFO, MD, COO & Member of Management Board	N/A	N/A	1974
Mr. Sean Marett	Chief Bus. Officer, Chief Commercial Officer & Member of Management Board	N/A	N/A	1966
Dr. Özlem Türeci	Chief Medical Officer & Member of Management Board	N/A	N/A	1968
Prof. Christoph Hubert Huber	Co-Founder & Member of Supervisory Board	N/A	N/A	1945
Mr. Ryan Richardson	Chief Strategy Officer, MD & Member of Management Board	N/A	N/A	1980
Sylke Maas	VP of Investor Relations and Bus. Strategy	N/A	N/A	N/A
Dr. James Timothy Patrick Ryan Ph.D.	VP of Legal & Intellectual Property	N/A	N/A	N/A
Michael Boehler	MD & Head of Global External Communications	N/A	N/A	N/A
Katalin Kariko	Sr. VP & Head of RNA Protein Replacement	N/A	N/A	N/A

Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in developing FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/II trial for prostate cancer; BNT113, which is in Phase I trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116, which is in preclinical trail for non-small cell lung cancer. It also develops neo-antigen specific immunotherapies, such as RO7198457, which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT152 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT212 for pancreatic and other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II a clinical trial to treat multiple solid tumors. Further, it develops MVT-5873, an IgG1 monoclonal antibody, which is in Phase I/II clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Genevant Sciences GmbH; Eli Lilly and Company; Bayer AG; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; Regeneron Pharmaceuticals, Inc.; and InstaDeep Ltd. The company was founded in 2008 and is headquartered in Mainz, Germany.

Corporate governance

BioNTech SE’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.